Market Summary
USD236.12-2.51
Delayedas of 03 Oct 2023, 12:04 pm-1.05%
PEN Stock Price
PEN RSI Chart
PEN Valuation
PEN Price/Sales (Trailing)
PEN Profitability
PEN Fundamentals
PEN Revenue
PEN Earnings
Price Action
52 Week Range
144.76348.67
(Low)(High)
Last 7 days
-3.4%
Last 30 days
-9.6%
Last 90 days
-29.6%
Trailing 12 Months
25.9%
PEN Financial Health
PEN Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for PEN
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-11 | Elsesser Adam | acquired | 74,911 | 7.75 | 9,666 | ceo and president |
2023-09-11 | Elsesser Adam | sold | -2,887,820 | 298 | -9,666 | ceo and president |
2023-09-08 | Kassing Don W. | sold | -128,165 | 288 | -444 | - |
2023-09-01 | Roberts Johanna | sold | -159,067 | 265 | -600 | evp, gen. counsel & secretary |
2023-09-01 | Grewal Harpreet | sold | -90,650 | 266 | -340 | - |
2023-09-01 | O'Rourke Bridget | sold | -26,662 | 266 | -100 | - |
2023-09-01 | Sarna Surbhi | sold | -22,662 | 266 | -85.00 | - |
2023-08-14 | Roberts Johanna | sold | -149,910 | 249 | -600 | evp, gen. counsel & secretary |
2023-08-11 | Elsesser Adam | acquired | 74,911 | 7.75 | 9,666 | ceo and president |
2023-08-11 | Elsesser Adam | sold | -2,389,570 | 247 | -9,666 | ceo and president |
Which funds bought or sold PEN recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-26 | BROOKFIELD Corp /ON/ | sold off | -100 | -981,825 | - | -% |
2023-09-21 | Baystate Wealth Management LLC | unchanged | - | 2,684 | 14,128 | -% |
2023-09-20 | BARCLAYS PLC | added | 208 | 6,489,000 | 8,799,000 | 0.01% |
2023-08-23 | WOLVERINE TRADING, LLC | new | - | 222,602 | 222,602 | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | unchanged | - | 274,554 | 1,445,050 | 0.01% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -2.12 | 2,616,290 | 15,169,600 | 0.02% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 19.92 | 823,066 | 2,536,880 | -% |
2023-08-21 | VisionPoint Advisory Group, LLC | new | - | 344 | 344 | -% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | added | 2.54 | 1,822,000 | 8,678,000 | 0.08% |
2023-08-17 | Coppell Advisory Solutions LLC | new | - | 47,029 | 47,029 | 0.01% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Penumbra
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 13, 2023 | capital research global investors | 6.1% | 2,321,719 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.13% | 3,467,792 | SC 13G/A | |
| Jan 23, 2023 | blackrock inc. | 11.6% | 4,422,738 | SC 13G/A | |
| Feb 11, 2022 | capital research global investors | 7.4% | 2,770,020 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
| Feb 04, 2022 | wellington management group llp | 0.00% | 14 | SC 13G/A | |
| Feb 03, 2022 | blackrock inc. | 9.0% | 3,356,220 | SC 13G/A | |
| Feb 16, 2021 | capital research global investors | 8.9% | 3,248,192 | SC 13G | |
| Feb 10, 2021 | vanguard group inc | 8.42% | 3,057,710 | SC 13G/A |
Recent SEC filings of Penumbra
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Oct 02, 2023 | 144 | Notice of Insider Sale Intent | |
| Oct 02, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 13, 2023 | 4 | Insider Trading | |
| Sep 12, 2023 | 4 | Insider Trading | |
| Sep 08, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 01, 2023 | 144 | Notice of Insider Sale Intent |
Peers (Alternatives to Penumbra)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
SYK | 104.0B | 19.5B | -3.73% | 35.20% | 38.38 | 5.34 | 10.36% | 30.30% |
ISRG | 103.6B | 6.7B | -4.97% | 57.37% | 72.72 | 15.55 | 11.75% | -0.66% |
BSX | 76.4B | 13.4B | -1.51% | 36.35% | 83.74 | 5.7 | 8.69% | 3.17% |
BDX | 71.3B | 19.0B | -7.43% | 16.56% | 44.09 | 3.79 | 0.46% | -5.24% |
EW | 42.1B | 5.7B | -9.43% | -16.28% | 30.27 | 7.43 | 5.64% | -4.53% |
| MID-CAP | ||||||||
PEN | 9.1B | 937.8M | -9.65% | 25.86% | 313.94 | 9.75 | 16.30% | 250.21% |
SWAV | 7.2B | 616.6M | -11.74% | -29.40% | 29.51 | 11.67 | 69.52% | 343.68% |
GMED | 5.0B | 1.1B | -8.56% | -16.75% | 23.67 | 4.54 | 12.63% | 50.85% |
IRTC | 2.8B | 452.1M | -10.08% | -26.48% | -28.35 | 6.22 | 24.99% | 24.09% |
TNDM | 1.4B | 790.3M | -21.04% | -54.04% | -6.37 | 1.81 | 3.21% | -1604.53% |
| SMALL-CAP | ||||||||
ATEC | 1.5B | 421.8M | -22.58% | 43.94% | -9.18 | 3.63 | 44.49% | -2.43% |
AVNS | 945.1M | 780.7M | -5.83% | -7.35% | -26.25 | 1.21 | 4.68% | -510.17% |
CSII | 839.3M | 239.8M | 0.70% | 0.15% | -22.16 | 3.5 | -4.74% | -31.15% |
SILK | 589.9M | 162.9M | -22.80% | -66.22% | -11.16 | 3.62 | 42.67% | 12.82% |
Penumbra News
Returns for PEN
Cumulative Returns on PEN
18.1%
7-Year Cumulative Returns
11.1%
5-Year Cumulative Returns
8.5%
3-Year Cumulative Returns
Risks for PEN
What is the probability of a big loss on PEN?
100%
Probability that Penumbra stock will be more than 20% underwater in next one year
58.9%
Probability that Penumbra stock will be more than 30% underwater in next one year.
18.9%
Probability that Penumbra stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does PEN drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Penumbra was unfortunately bought at previous high price.
Drawdowns
Financials for Penumbra
Income Statement (Last 12 Months)(In Thousands)
| Income Statement (Last 12 Months) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 6.0% | 937,791 | 884,636 | 847,133 | 829,928 | 806,367 | 782,281 | 747,590 | 710,477 | 671,436 | 592,287 | 560,412 | 538,777 | 527,203 | 556,295 | 547,405 | 522,935 | 495,239 | 470,676 | 444,938 | 420,196 | 392,301 |
| Gross Profit | 5.9% | 591,687 | 558,861 | 535,207 | 522,227 | 506,812 | 491,463 | 475,382 | 444,248 | 415,259 | 361,503 | 338,175 | 341,990 | 347,065 | 376,063 | 371,964 | 352,548 | 331,562 | 309,886 | 292,533 | 277,548 | 257,313 |
| Operating Expenses | 2.7% | 555,523 | 540,725 | 529,125 | 561,035 | 542,273 | 516,473 | 482,883 | 413,437 | 413,387 | 387,592 | 377,117 | 368,608 | 340,549 | 339,097 | 324,456 | 308,950 | 321,789 | 303,631 | 293,385 | 281,213 | 239,446 |
| S&GA Expenses | 2.8% | 474,716 | 461,896 | 449,718 | 447,588 | 433,412 | 409,433 | 378,331 | 341,434 | 323,195 | 292,413 | 287,068 | 285,153 | 278,284 | 286,095 | 272,733 | 259,221 | 245,866 | 232,977 | 226,385 | 216,679 | 206,707 |
| R&D Expenses | 3.2% | 83,791 | 81,153 | - | 81,924 | 75,809 | 73,381 | - | 70,064 | 94,316 | 100,965 | - | 94,125 | 65,872 | 53,521 | - | 49,729 | 45,088 | 39,819 | 36,165 | 33,699 | 32,739 |
| EBITDA | -100.0% | - | 42,818 | 28,213 | -20,557 | -18,402 | -9,410 | 5,906 | 44,054 | 16,251 | -11,402 | -25,127 | -14,011 | 17,393 | 46,739 | 58,239 | 53,234 | - | - | - | - | - |
| EBITDA Margin | -100.0% | - | 0.05* | 0.03* | -0.02* | -0.02* | -0.01* | 0.01* | 0.06* | 0.02* | -0.02* | -0.04* | -0.03* | 0.03* | 0.08* | 0.11* | 0.10* | - | - | - | - | - |
| Earnings Before Taxes | 117.3% | 38,351 | 17,648 | 3,892 | -44,190 | -39,443 | -28,073 | -10,502 | 29,941 | 2,428 | -24,805 | -38,018 | -25,758 | 6,936 | 37,480 | 50,135 | 45,735 | 12,864 | 9,013 | 1,608 | -1,835 | 19,312 |
| EBT Margin | -100.0% | - | 0.02* | 0.00* | -0.05* | -0.05* | -0.04* | -0.01* | 0.04* | 0.00* | -0.04* | -0.07* | -0.05* | 0.01* | 0.07* | 0.09* | 0.09* | - | - | - | - | - |
| Net Income | 349.4% | 29,128 | 6,481 | -2,002 | -30,512 | -19,391 | -6,473 | 5,284 | 33,565 | 15,900 | -5,291 | -15,702 | -9,661 | 10,637 | 39,185 | 48,458 | 45,428 | 15,015 | 11,808 | 6,601 | 9,025 | 28,193 |
| Net Income Margin | -100.0% | - | 0.01* | 0.00* | -0.04* | -0.02* | -0.01* | 0.01* | 0.05* | 0.02* | -0.01* | -0.03* | -0.02* | 0.02* | 0.07* | 0.09* | 0.09* | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -56,253 | -74,959 | -90,096 | -40,191 | -2,790 | -11,678 | -152 | -38,503 | -60,306 | -57,998 | -55,379 | -33,543 | -6,977 | 4,543 | 12,251 | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 |
| Assets | 2.7% | 1,433 | 1,395 | 1,371 | 1,322 | 1,328 | 1,302 | 1,244 | 973 | 841 | 823 | 810 | 780 | 664 | 666 | 614 | 585 | 569 | 515 | 501 | 499 | 490 |
| Current Assets | 5.3% | 828 | 786 | 756 | 724 | 718 | 690 | 681 | 668 | 635 | 618 | 590 | 576 | 454 | 463 | 451 | 435 | 423 | 411 | 398 | 392 | 388 |
| Cash Equivalents | 20.6% | 114 | 95.00 | 70.00 | 55.00 | 58.00 | 68.00 | 59.00 | 66.00 | 56.00 | 70.00 | 80.00 | 134 | 72.00 | 73.00 | 112 | 77.00 | 96.00 | 68.00 | 48.00 | 60.00 | 51.00 |
| Inventory | 4.3% | 359 | 344 | 334 | 320 | 296 | 274 | 264 | 258 | 245 | 220 | 192 | 183 | 166 | 153 | 140 | 133 | 122 | 116 | 110 | 98.00 | 95.00 |
| Net PPE | 1.1% | 66.00 | 65.00 | 65.00 | 64.00 | 63.00 | 60.00 | 59.00 | 57.00 | 50.00 | 48.00 | 65.00 | 62.00 | 59.00 | 52.00 | 46.00 | 38.00 | 35.00 | 35.00 | 34.00 | 34.00 | 32.00 |
| Goodwill | 0.0% | 166 | 166 | 166 | 165 | 166 | 166 | 166 | 159 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 7.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 |
| Liabilities | -1.3% | 366 | 371 | 372 | 348 | 358 | 342 | 290 | 289 | 190 | 185 | 191 | 157 | 176 | 180 | 147 | 131 | 132 | 135 | 92.00 | 74.00 | 75.00 |
| Current Liabilities | -1.5% | 144 | 146 | 145 | 138 | 146 | 130 | 123 | 116 | 112 | 106 | 108 | 78.00 | 88.00 | 91.00 | 86.00 | 70.00 | 69.00 | 66.00 | 65.00 | 50.00 | 50.00 |
| Shareholder's Equity | 4.1% | 1,067 | 1,024 | 999 | 974 | 970 | 959 | 954 | 685 | 650 | 638 | 620 | 623 | 488 | 486 | 467 | 454 | 437 | 422 | 409 | 425 | 415 |
| Retained Earnings | 36.1% | 71.00 | 52.00 | 44.00 | 40.00 | 42.00 | 46.00 | 46.00 | 71.00 | 52.00 | 41.00 | 37.00 | 46.00 | 58.00 | 58.00 | 48.00 | 36.00 | 20.00 | 9.00 | 2.00 | 21.00 | 8.00 |
| Additional Paid-In Capital | 2.2% | 1,001 | 979 | 963 | 947 | 938 | 919 | 911 | 621 | 603 | 598 | 585 | 581 | 436 | 431 | 423 | 419 | 420 | 415 | 408 | 404 | 404 |
| Shares Outstanding | 0.4% | 38.00 | 38.00 | 38.00 | 38.00 | 38.00 | 38.00 | 38.00 | 37.00 | 36.00 | 36.00 | 36.00 | 35.00 | 35.00 | 35.00 | 35.00 | 35.00 | 35.00 | 34.00 | 34.00 | 34.00 | 34.00 |
| Minority Interest | - | - | - | - | - | - | - | - | -6.20 | -4.62 | -3.71 | -2.69 | -1.63 | -0.82 | -0.28 | -0.39 | 0.00 | -0.07 | 0.00 | -0.13 | - | - |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 149.1% | 19.00 | -38.02 | -55.66 | -66.27 | -16.91 | 19.00 | 10.00 | 17.00 | -23.31 | -41.69 | -33.24 | -26.39 | -0.79 | 23.00 | 27.00 | 29.00 | 18.00 | 16.00 | 29.00 | 20.00 | 21.00 |
| Share Based Compensation | 9.8% | 45.00 | 41.00 | 37.00 | 69.00 | 67.00 | 68.00 | 66.00 | 32.00 | 30.00 | 26.00 | 26.00 | 23.00 | 23.00 | 22.00 | 21.00 | 21.00 | 20.00 | 19.00 | 18.00 | 18.00 | 18.00 |
| Cashflow From Investing | -54.9% | 22.00 | 50.00 | 55.00 | 45.00 | -14.80 | -9.11 | -21.73 | -30.62 | -30.21 | -111 | -104 | -137 | -73.96 | -34.53 | -12.71 | 41.00 | 6.00 | 34.00 | -0.38 | -26.40 | -29.58 |
| Cashflow From Financing | -2.8% | 15.00 | 16.00 | 12.00 | 9.00 | 7.00 | 1.00 | 1.00 | 0.00 | 1.00 | 137 | 135 | 132 | 132 | -11.60 | -8.96 | -5.29 | -4.90 | -4.78 | -9.81 | -10.54 | -10.19 |
PEN Income Statement
2023-06-30Condensed Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Income Statement [Abstract] | ||||
| Revenue | $ 261,499 | $ 208,344 | $ 502,897 | $ 412,239 |
| Cost of revenue | 94,638 | 74,309 | 184,964 | 150,786 |
| Gross profit | 166,861 | 134,035 | 317,933 | 261,453 |
| Operating expenses: | ||||
| Research and development | 21,537 | 19,559 | 41,523 | 40,123 |
| Sales, general and administrative | 127,435 | 114,615 | 250,513 | 225,515 |
| Total operating expenses | 148,972 | 134,174 | 292,036 | 265,638 |
| Income (loss) from operations | 17,889 | (139) | 25,897 | (4,185) |
| Interest income (expense), net | 839 | (72) | 1,393 | (119) |
| Other income (expense), net | 808 | (956) | 898 | (1,967) |
| Income (loss) before income taxes | 19,536 | (1,167) | 28,188 | (6,271) |
| Provision for (benefit from) income taxes | 576 | 2,520 | 666 | (2,663) |
| Net income (loss) | $ 18,960 | $ (3,687) | $ 27,522 | $ (3,608) |
| Net income (loss) per share: | ||||
| Basic (in dollars per share) | $ 0.49 | $ (0.10) | $ 0.72 | $ (0.10) |
| Diluted (in dollars per share) | $ 0.48 | $ (0.10) | $ 0.70 | $ (0.10) |
| Weighted average shares outstanding: | ||||
| Basic (in shares) | 38,320,999 | 37,767,519 | 38,254,042 | 37,707,156 |
| Diluted (in shares) | 39,201,155 | 37,767,519 | 39,151,412 | 37,707,156 |
PEN Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 114,167 | $ 69,858 |
| Marketable investments | 106,896 | 118,172 |
| Accounts receivable, net of allowance for credit losses of $4,775 and $862 at June 30, 2023 and December 31, 2022, respectively | 208,965 | 203,384 |
| Inventories | 358,770 | 334,006 |
| Prepaid expenses and other current assets | 39,078 | 30,279 |
| Total current assets | 827,876 | 755,699 |
| Property and equipment, net | 65,958 | 65,015 |
| Operating lease right-of-use assets | 187,494 | 192,636 |
| Finance lease right-of-use assets | 31,751 | 33,323 |
| Intangible assets, net | 76,116 | 81,161 |
| Goodwill | 166,166 | 166,046 |
| Deferred taxes | 66,671 | 64,213 |
| Other non-current assets | 10,500 | 12,793 |
| Total assets | 1,432,532 | 1,370,886 |
| Current liabilities: | ||
| Accounts payable | 25,819 | 26,679 |
| Accrued liabilities | 105,606 | 106,300 |
| Current operating lease liabilities | 10,715 | 10,033 |
| Current finance lease liabilities | 1,984 | 1,920 |
| Total current liabilities | 144,124 | 144,932 |
| Non-current operating lease liabilities | 194,655 | 198,955 |
| Non-current finance lease liabilities | 23,922 | 24,865 |
| Other non-current liabilities | 3,288 | 3,276 |
| Total liabilities | 365,989 | 372,028 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Common stock | 38 | 38 |
| Additional paid-in capital | 1,000,658 | 963,040 |
| Accumulated other comprehensive loss | (5,579) | (8,124) |
| Retained earnings | 71,426 | 43,904 |
| Total Penumbra, Inc. stockholders’ equity | 1,066,543 | 998,858 |
| Total liabilities and stockholders’ equity | $ 1,432,532 | $ 1,370,886 |
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.